Thrive Capital Management (Pennsylvania)’s Iovance Biotherapeutics IOVA Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,050	Closed	-$33.5K	–	178
2025 Q1	$33.5K	Hold	10,050	–	–	0.02%	113
2024 Q4	$74.4K	Hold	10,050	–	–	0.03%	95
2024 Q3	$94.4K	Hold	10,050	–	–	0.04%	176
2024 Q2	$80.6K	Buy	10,050 +50	+0.5%	+$536	0.04%	177
2024 Q1	$148K	Hold	10,000	–	–	0.08%	118
2023 Q4	$81.3K	Hold	10,000	–	–	0.04%	154
2023 Q3	$45.5K	Buy	+10,000	New	+$65.3K	0.03%	135

Other funds holding IOVA

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s IOVA Position: Q2 2025 in Review

Thrive Capital Management (Pennsylvania) sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 10,050 shares — an estimated $33.5K sold.

Thrive Capital Management (Pennsylvania) first reported a position in IOVA in Q3 2023 and held it in 7 quarters. The position peaked at $148K in Q1 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

Thrive Capital Management (Pennsylvania) reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
Thrive Capital Management (Pennsylvania) sold 10,050 Iovance Biotherapeutics shares in Q2 2025, an estimated $33.5K.
Thrive Capital Management (Pennsylvania) first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 7 quarters.
Thrive Capital Management (Pennsylvania)'s Iovance Biotherapeutics position peaked at $148K in Q1 2024.
254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q2 2025, filed 8 Aug 2025.